BioMarin Pharmaceuticals BMRN Net debt
Discontinued — last reported Q1 '26
Net debt at other companies
Other financials
Where this comes from
Calculated from BioMarin Pharmaceuticals’s reported figures.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's net debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's net debt?
- BioMarin Pharmaceuticals (BMRN) reported net debt of -$1.64B in Q1 2026.
- How has BioMarin Pharmaceuticals's net debt changed year-over-year?
- BioMarin Pharmaceuticals's net debt decreased by 265.9% year-over-year, from -$448.8M to -$1.64B.
- What is the long-term trend for BioMarin Pharmaceuticals's net debt?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's net debt has grown at a 2.4% compound annual growth rate (CAGR), from -$592.92M to -$668.81M.
- What does net debt mean?
- Debt left over after using all the company's cash to pay it down.
- How do you interpret net debt?
- A negative value means net cash — more cash than debt, a position of strength. The numerator of net-debt/EBITDA, the most common leverage yardstick.
- How does net debt compare across companies?
- Most informative as net-debt/EBITDA; cash-rich balance sheets can show large total debt yet little or negative net debt.